Celgene Corp. has made its first big foray into CNS by inking a strategic drug discovery and development collaboration with Germany's Evotec AG to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases.
Celgene Joins Evotec In Its First Neurodegenerative Drug Discovery Effort
Evotec has landed a strategic partnership with Celgene worth up to $295m in neurodegeneration drug discovery based on the German CRO's induced pluripotent stem cell platform.
More from Neurological
More from Therapy Areas
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.